Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages

  Veldhuis Vlug, A G ^a   El Mahdiui, M ^a   Endert, E ^a   Heijboer, A C ^b   Fliers, E ^a   Bisschop, P H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CORTICOSTEROID; METADRENALIN; PROCOLLAGEN C PROTEINASE; THIAZIDE DIURETIC AGENT;

ADRENALECTOMY; ADRENERGIC SYSTEM; ADULT; ARTICLE; BONE REMODELING; BONE TURNOVER; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCREENING; URINARY EXCRETION;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ADULT; AGED; BONE RESORPTION; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RETROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

RODENTIA;

EID: 84868623601     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2823     Document Type: Article

References (17)

1. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207 (Pubitemid 30064908)
2. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520 (Pubitemid 40477060)
3. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317 (Pubitemid 35345151)
4. Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D 2006 Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318:1118-1127 (Pubitemid 44274974)
5. Kondo H, Togari A 2011 Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88:23-32
6. Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada MN, Richard O, Vico L, Collomp K, Courteix D 2005 Severe bone alterations under β2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 37:622-633 (Pubitemid 41476384)
7. Wiens M, Etminan M, Gill SS, Takkouche B 2006 Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350-362 (Pubitemid 44370908)
8. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP 2007 Use of β-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16:612-619 (Pubitemid 47039527)
9. Vestergaard P, Rejnmark L, Mosekilde L 2007 Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132:1599-1607 (Pubitemid 350156018)
10. Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P, Rossi S, Crepaldi G, Nuti R 2010 Effect of inhaled glucocorticoids and β(2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 87:137-143
11. Lenders JW, Eisenhofer G, Mannelli M, Pacak K 2005 Phaeochromocytoma. Lancet 366:665-675 (Pubitemid 41176020)
12. Bisschop PH, Corssmit EP, Baas SJ, Serlie MJ, Endert E, Wiersinga WM, Fliers E 2009 Evaluation of endocrine tests. C: glucagon and clonidine test in phaeochromocytoma. Neth J Med 67:91-95
13. Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF 2011 Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskeletal Disorders 12:167-172
14. de Jong WH, Graham KS, van der Molen JC, Links TP, Morris MR, Ross HA, de Vries EG, Kema IP 2007 Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem 53:1684-1693 (Pubitemid 47340066)
15. Huang HH, Brennan TC, Muir MM, Mason RS 2009 Functional α1- and β2-adrenergic receptors in human osteoblasts. J Cell Physiol 220:267-275
16. Seeman E, Delmas PD 2006 Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
17. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA 2011 Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420